• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cellectis S.A. - American Depositary Shares (NQ:CLLS)

    3.520 +0.100 (+2.92%)
    Streaming Delayed Price Updated: 9:46 AM EDT, Aug 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,275
    Open 3.550
    Bid (Size) 3.490 (2,000)
    Ask (Size) 3.600 (1,700)
    Prev. Close 3.420
    Today's Range 3.520 - 3.600
    52wk Range 2.350 - 5.480
    Shares Outstanding 45,484,310
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Cellectis Reports Financial Results for the Second Quarter 2026
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis to Report Second Quarter Financial Results on August 6, 2026
    From Cellectis Inc.
    Via GlobeNewswire

    Performance

    YTD
    -26.7%
    -26.7%
    1 Month
    +21.8%
    +21.8%
    3 Month
    -3.0%
    -3.0%
    6 Month
    -15.8%
    -15.8%
    1 Year
    +35.9%
    +35.9%

    More News

    Read More
    News headline image
    Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
    From ProLynx Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
    Via The Motley Fool
    Topics Intellectual Property Regulatory Compliance
    News headline image
    Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
    Via The Motley Fool
    Topics Economy Regulatory Compliance
    News headline image
    Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Reports Financial Results for the First Quarter 2026
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis to Report First Quarter Financial Results on May 11, 2026
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis’ Allogeneic CAR-T Platform
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
    Via The Motley Fool
    News headline image
    Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Announces 2026 Strategy and Catalysts
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Traders are paying attention to the gapping stocks in Monday's session. ↗
    Via Chartmill
    News headline image
    Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
    From Allogene Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Announces Arbitral Decision in Dispute with Servier
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Why Cellectis Stock Is Trading Higher Today ↗
    Via Benzinga
    News headline image
    European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
    Via MarketMinute
    Topics Artificial Intelligence Economy Supply Chain
    News headline image
    Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
    From Cellectis Inc.
    Via GlobeNewswire
    News headline image
    Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Cellectis Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Cellectis S.A. - American Depositary Shares publicly traded?
    Yes, Cellectis S.A. - American Depositary Shares is publicly traded.
    What exchange does Cellectis S.A. - American Depositary Shares trade on?
    Cellectis S.A. - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Cellectis S.A. - American Depositary Shares?
    The ticker symbol for Cellectis S.A. - American Depositary Shares is CLLS on the Nasdaq Stock Market
    What is the current price of Cellectis S.A. - American Depositary Shares?
    The current price of Cellectis S.A. - American Depositary Shares is 3.520
    When was Cellectis S.A. - American Depositary Shares last traded?
    The last trade of Cellectis S.A. - American Depositary Shares was at 08/27/26 09:46 AM ET
    What is the market capitalization of Cellectis S.A. - American Depositary Shares?
    The market capitalization of Cellectis S.A. - American Depositary Shares is 160.10M
    How many shares of Cellectis S.A. - American Depositary Shares are outstanding?
    Cellectis S.A. - American Depositary Shares has 160M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.